butabarbital
Trade name: neonal
Approved
Jun 5, 1939
Barbiturates are non-selective depressants of the central nervous system. Butabarbital is one of them, which is used under brand name butisol sodium as a sedative or hypnotic. Like other barbiturates, butabarbital is capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. The mechanism of action by which barbiturates exert their effect is not yet completely understood, but is assumed, that butabarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 17 marketing orgs
Timeline
1930s
- Jun 5, 1939
Earliest FDA Approval
- Jun 5, 1939
Mylan — NDA Secondary Org
- Jun 5, 1939
PHARMOBEDIENT — Marketing Organization
1970s
- Sep 25, 1973
Teva — Marketing Organization
- Jan 15, 1974
Marshall Pharma — Marketing Organization
- Jan 28, 1974
Whiteworth Towne Paulsen — Marketing Organization
- Jun 14, 1974
Solvay — Marketing Organization
- Feb 11, 1976
Halsey — Marketing Organization
- Aug 15, 1977
Hikma — Marketing Organization
- Aug 24, 1977
Watson Pharmaceuticals — Marketing Organization
- Apr 10, 1978
Meda Pharmaceuticals — Marketing Organization
- Apr 11, 1978
Medpointe — Marketing Organization
- May 17, 1978
Alpharma — Marketing Organization
- May 31, 1978
Bundy — Marketing Organization
- Jul 20, 1978
Lannett Company, Inc. — Marketing Organization
- Feb 26, 1979
Wockhardt — Marketing Organization
1980s
- Dec 22, 1981
Sandoz — Marketing Organization
Indications
Mechanism of action
- GABA-A receptor; anion channelPOSITIVE ALLOSTERIC MODULATOR
GABA-A receptor; anion channel positive allosteric modulator
Barbiturate site
- Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1) ↗
- Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2) ↗
- Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2) ↗
- Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3) ↗
- Gamma-aminobutyric acid receptor subunit alpha-4 (GABRA4) ↗
- Gamma-aminobutyric acid receptor subunit gamma-3 (GABRG3) ↗
- Gamma-aminobutyric acid receptor subunit theta (GABRQ) ↗
- Gamma-aminobutyric acid receptor subunit alpha-3 (GABRA3) ↗
- Gamma-aminobutyric acid receptor subunit pi (GABRP) ↗
- Gamma-aminobutyric acid receptor subunit delta (GABRD) ↗
- Gamma-aminobutyric acid receptor subunit gamma-1 (GABRG1) ↗
- Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) ↗
- Gamma-aminobutyric acid receptor subunit epsilon (GABRE) ↗
- Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2) ↗
- Gamma-aminobutyric acid receptor subunit alpha-5 (GABRA5) ↗
- Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6) ↗
- GABA receptor alpha-1 subunit
- GABA receptor beta-2 subunit
- GABA receptor alpha-4 subunit
- GABA receptor delta subunit
- GABA receptor alpha-5 subunit
- GABA receptor alpha-6 subunit
- GABA receptor beta-3 subunit
- GABA receptor alpha-3 subunit
- GABA receptor alpha-2 subunit
- GABA-A receptor; GABA-A site (alpha1/beta2 interface)
- GABA-A receptor; alpha-3/beta-3/gamma-2
- GABA-A receptor; alpha-1/beta-3/gamma-2
- GABA-A receptor; alpha-5/beta-3/gamma-2
- GABA-A receptor; alpha-2/beta-3/gamma-2
- GABA-A receptor; alpha-1/beta-2/gamma-2
- GABA-A receptor; alpha-6/beta-3/gamma-2
- GABA-A receptor; benzodiazepine site
- GABA-A receptor; agonist GABA site
- GABA A receptor alpha-2/beta-2/gamma-2
- GABA A receptor alpha-3/beta-2/gamma-2
- GABA A receptor alpha-6/beta-2/gamma-2
- GABA A receptor alpha-1/beta-1/gamma-2
- GABA A receptor alpha-4/beta-3/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta
- Gamma-aminobutyric acid receptor subunit alpha-1/ beta-1
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-3/ beta-2
- Gamma-aminobutyric acid receptor subunit alpha-3/ beta-3/gamma-3
- Gamma-aminobutyric acid receptor subunit alpha-3/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-3/beta-3/theta
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-3/gamma-3
- Gamma-aminobutyric acid receptor subunit alpha-6/beta-3
- GABA-A receptor alpha-1/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-1/beta-2/delta
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-2/delta
- Gamma-aminobutyric acid receptor subunit beta-1/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-1/alpha-2/beta-2/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-1/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-2/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-1/delta
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-2/gamma-2
- GABA receptor beta-1 subunit
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-1/gamma-2
Approval history
- approvedJun 5, 1939
Chemistry & pharmacology
SMILES
CCC(C)C1(CC)C(=O)NC(=O)NC1=O- Mol. weight
- 212.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL449 ↗
- WikipediaButabarbital ↗
- NCATSP0078O25A9 ↗
- ChEMBLCHEMBL404422 ↗
- ChEMBLCHEMBL1200982 ↗
Also known as
- 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(1-methylpropyl)-, monosodium salt
- 5-butyl-5-ethylbarbituric acid
- 5-ethyl-5-(1-methylpropyl)-2,4,6(1h,3h,5h)-pyrimidinetrione
- 5-ethyl-5-(1-methylpropyl)-2,4,6(1h,3h,5h)-pyrimidinetrione
- 5-ethyl-5-(1-methylpropyl)barbituric acid
- 5-ethyl-5-(1-methylpropyl)barbituric acid
- 5-sec-butyl-5-ethyl-2,4,6(1h,3h,5h)-pyrimidinetrione
- 5-sec-butyl-5-ethyl-2,4,6(1h,3h,5h)-pyrimidinetrione
- 5-sec-butyl-5-ethylbarbituric acid
- 5-sec-butyl-5-ethylbarbituric acid
- 5-sec-butyl-5-ethylpyrimidine-2,4,6(1h,3h,5h)-trione
- 5-sec-butyl-5-ethylpyrimidine-2,4,6(1h,3h,5h)-trione
- butabarb
- butabarb
- butabarb
- butabarbital
- butabarbital
- butabarbital
- butabarbital
- butabarbital
- butabarbital
- butabarbital
- butabarbital
- butabarbital sodium
- butabarbital sodium
- butabarbital sodium
- butabarbital sodium
- butabarbital sodium
- butabarbitone
- butabarbitone
- butalan
- butalan
- butatab
- buticaps
- buticaps
- butisol
- butisol
- butisol
- butisol sodium
- butisol sodium
- butisol sodium
- fiornal
- halsey drug brand of butabarbital sodium
- neonal
- neonal
- neonal
- sarisol
- sarisol
- sarisol
- sarisol no. 1
- sarisol no. 1
- sarisol no. 2
- sarisol no. 2
- secbubarbital
- secbutabarbital
- secbutabarbital
- secbutabarbital
- secbutabarbital
- secbutabarbital
- secbutabarbital
- secbutabarbital sodium
- secbutabarbital sodium
- secbutabarbital sodium
- secbutobarbitone
- secbutobarbitone
- secbutobarbitone
- secbutobarbitone
- secumalum
- sodium butabarbital
- sodium butabarbital
- soneryl
- soneryl
- soneryl
- wallace brand of butabarbital sodium
Organizations
Marketing (18)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alpharma | For profit | MKTG | May 17, 1978 |
| Bundy | For profit | MKTG | May 31, 1978 |
| Halsey | For profit | MKTG | Feb 11, 1976 |
| Hikma | For profit | MKTG | Aug 15, 1977 |
| Hikma | For profit | SYN | Aug 15, 1977 |
| Lannett Company, Inc. | For profit | MKTG | Jul 20, 1978 |
| Marshall Pharma | For profit | MKTG | Jan 15, 1974 |
| McNeil | For profit | NDA | — |
| Meda Pharmaceuticals | For profit | MKTG | Apr 10, 1978 |
| Medpointe | For profit | MKTG | Apr 11, 1978 |
| Mylan | For profit | NDA2 | Jun 5, 1939 |
| PHARMOBEDIENT | For profit | MKTG | Jun 5, 1939 |
| Sandoz | For profit | MKTG | Dec 22, 1981 |
| Solvay | For profit | MKTG | Jun 14, 1974 |
| Teva | For profit | MKTG | Sep 25, 1973 |
| Watson Pharmaceuticals | For profit | MKTG | Aug 24, 1977 |
| Whiteworth Towne Paulsen | For profit | MKTG | Jan 28, 1974 |
| Wockhardt | For profit | MKTG | Feb 26, 1979 |